miR-944 in cancer: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Camila Xu and Version 1 by Shiwei Duan.

miR-944 is localized in intron 4 of TP63. ΔNp63 in intron 3 of TP63 recruits the transcription factor AP-2 to promote miR-944 gene expression, which mediates epidermal differentiation induction by ΔNp63. miR-944 is dysregulated in various cancers. In squamous cell carcinoma. miR-944 can target and inhibit 27 protein-coding genes, thereby regulating cell cycle, proliferation, apoptosis, epithelial mesenchymal transition, cancer cell invasion and migration, and other cell behaviors. The genes targeted by miR-944 are involved in three signaling pathways, including the Wnt/β-catenin pathway, Jak/STAT3 pathway, and PI3K/AKT pathway. miR-944 was regulated by a total of 11 competing endogenous RNAs, including 6 circular RNAs and 5 long non-coding RNAs. Abnormally expressed miR-944 can act as an independent prognostic factor and is closely related to tumor invasion, lymph node metastasis, TNM staging, and drug resistance. miR-944 is expected to become a critical biomarker with great clinical application value in cancer.

  • miR-944
  • ceRNA
  • dysregulation
  • diagnosis

1. Introduction

microRNAs (miRNAs) are endogenous short non-coding RNAs of approximately 22 nt that typically target the 3’ untranslated region (3’-UTR) of mRNAs [1], thereby inhibiting the function of protein-coding genes [2]. Dysregulation of miRNAs is often associated with the malignant transformation of cells, thereby participating in biological processes that promote cancer progression, metastasis, and treatment resistance [3,4][3][4].
miR-944 is located in the fourth intron of tumor protein p63 (TP63) in the chromosome 3q28 region [5] and produced at the 3’ end of the stem-loop structure of pre-mir-944. miR-944 is aberrantly expressed in more than 10 cancers. Targeted inhibition of mRNA by miRNA can be hindered by competing endogenous RNAs (ceRNAs), such as circular RNAs (circRNAs) and long non-coding RNAs (lncRNAs) [6]. miR-944 is regulated by eleven ceRNAs, including six circRNAs and five lncRNAs. miR-944 can target and suppress 27 protein-coding genes, thereby regulating cancer cell behaviors such as cancer cell cycle, growth, proliferation, epithelial-mesenchymal transition (EMT), cancer cell invasion, and metastasis. The genes targeted by miR-944 are involved in three signaling pathways, including the Wnt/β-catenin pathway, the Jak/STAT3 pathway, and the PI3K/AKT pathway.
In patients with nasopharyngeal carcinoma (NPC) [7], colorectal cancer (CRC) [8[8][9],9], or breast cancer (BrC) [10], low expression of miR-944 was not only associated with poorer overall survival (OS) but also with more advanced tumor infiltration, more lymph node metastasis, and more advanced tumor node metastasis (TNM) stage [9]. miR-944 is associated with resistance to four anticancer drugs, including cisplatin (DDP) [11], rapamycin (RAPA) [12], doxorubicin (DOX) [13], and paclitaxel (PTX) [14]. miR-944 is involved in the molecular mechanism of action of two anticancer drugs, including the quinazolidine alkaloid matrine [15] and a drug under clinical trials, 188Re-liposome [16].

2. miR-944 and Its Host Gene TP63

The p63 transcription factor encoded by TP63, the host gene of miR-944, is a tumor suppressor gene belonging to the p53 family [17]. N-terminal truncated isoform of p63 (ΔNp63), which is transcribed from an alternative promoter in intron 3 of TP63, can regulate the epithelial properties of cells and play an important role in the terminal differentiation and stemness maintenance of basal epidermal cells [18]. miR-944 was significantly positively correlated with ΔNp63 expression in cervical cancer (CxCa) and jointly exerted a cancer-promoting effect [19]. During the differentiation of human epidermal keratinocytes, ΔNp63 can recruit the transcription factor AP-2 to the promoter region of the miR-944 gene, thereby promoting the expression of miR-944 and inducing epidermal differentiation [17].

3. Aberrant Expression of miR-944 in Cancer

As shown in Table 1, miR-944 is downregulated in cells and tissues of 11 cancers. Meanwhile, miR-944 is lowly expressed in the plasma of esophageal cancer (ECa) [20]. It is worth noting that miR-944 is highly expressed in cancer tissues of LUSC [21] and endometrial carcinoma (EC) [22], as well as CxCa cell lines, serum, and tissues [5,23,24,25][5][23][24][25]. Furthermore, the expression of miR-944 in BrC is controversial. Specifically, miR-944 was highly expressed in serum and tissues of BrC [26], whereas miR-944 was found to be downregulated in five BrC cell lines and tissues [27].
Table 1.
 Aberrant expression of miR-944 in different cancers.
Physiological System Cancer miR-944 Expression Cell Line Tissue or Serum Ref.
Nervous system GBM/LGG Downregulated HA1800 versus SHG44, U87MG, and U251MG Paracancerous tissues versus glioma tissues from 5 patients [ 405/1828]
Upregulated; Q4 Not studied Respiratory system NPC
BRCA 624/74Downregulated NP69 versus C666-1, CNE1, CNE2, and HNE1 Paracancerous tissues versus tumor tissues from 20 NPC patients Downregulated; Q4 Downregulated in BrC tissues and BrC cells (MDA-MB-231, MCF-7, MDA-MB-453, ZR-75, and T47-D) [27]; and Upregulated in BrC tissues and serum sample of BrC patients [26][29]
Downregulated
CHOLNP69 versus CNU46, SUNE1, HONE1, 6–10 B, CNE1, CNE2, and HNE1 Nasopharyngeal mucosa tissues from 30 healthy people versus primary tumor tissues from 30 NPC patients [7]
20/8 ns; Q3 Not studied LUAD Downregulated 16HBE versus A549, H1299, SK-Lu-1, and PC-9
ESCA 176/8Paracancerous tissues versus LUAD tissues from 25 patients ns; Q4 Downregulated in ECa tissues and serums of ECa patients [20][30]
LUSC Upregulated — Paracancerous tissues from patients versus SCC tissues from patients [21]
GBM/LGG 209/3 ns; Q3 Downregulated in GBM/LGG tissues and GBM/LGG cells (SHG44, U87MG, and U251MG) [28] NSCLC Downregulated BEAS-2B versus H522 and H1975 —
HNSC 485/44[15]
Upregulated; Q4 Not studied Downregulated BEAS-2B versus H358, H1299, PC-9, and A549 Paracancerous tissues versus tumor tissues from 65 NSCLC patients [31]
KICH 49/8 ns; Q3 Not studied Downregulated BEAS-2B versus A549, H226, H292, ANP973, and H1299 Paracancerous tissues versus tumor tissues from 60 NSCLC patients [
KIRC 108/1932]
ns; Q3 Not studied Downregulated — Paracancerous tissues versus tumor tissues from 9 NSCLC patients
KIRP[2]
155/23 ns; Q3 Not studied Digestive system TSCC Downregulated normal gingival epithelial cells versus SCC-9, CAL-27, and SCC-15 Paracancerous tissues versus TSCC tissues from 57 patients [33]
LIHC 324/47 ns; Q4 Downregulated in HCC tissues and HCC cells (Hep3B, Bel-7402, SMMC-7721, Huh7, and SK-HEP-1) [36] ECa Downregulated — Paracancerous tissues versus adenocarcinoma tissues from 59 eca patients; serum exosomes from healthy persons versus serum exosomes from 59 eca patients [20]
GC Downregulated GES-1 versus AGS, MKN-1, HGC-27, MKN-45, SGC-7901, and BGC-823 —
LUAD 430/40 ns; Q4 Downregulated in LUAD tissues and LUAD cells (A549, H1299, SK-Lu-1, and PC-9) [30] [34]
LUSC 334/44 Upregulated; Q4 Upregulated in LUSC tissues [21] Downregulated GES-1 versus SGC-7901, MGC-803, MKN-28, and BGC-823 Paracancerous tissues versus tumor tissues from 40 GC patients [35]
PRAD 437/50 Downregulated; Q4 Not studied HCC Downregulated L02 versus Hep3B, Bel-7402, SMMC-7721, Huh7, and SK-HEP-1 Paracancerous tissues versus tumor tissues from 61 HCC patients [36]
STAD 303/26 ns; Q3 Downregulated in GC tissues and GC cells (AGS, MKN-1, HGC-27, MKN-45, SGC-7901, MGC-803, BGC-823, and MKN-28) [34,35][34][35] CRC Downregulated
THCA 420/50HIEC and HEK293 versus HCT116, Caco-2, HT29, SW620, and SW480 — [9]
Upregulated; Q4 Not studied Downregulated COS7 versus HCT116, LoVo, RKO, HCT15, HT29, SW480, and SW620 — [37]
Downregulated
UCEC 330/26 Upregulated; Q3 Upregulated in EC tissues [22 — Paracancerous tissues versus fresh CRC tissues from 140 CRC patients [8]
Downregulated CCC-HIE-2 versus HT-29, HCT116, SW480, and SW620 Paracancerous tissues versus fresh CRC tissues from 100 CRC patients [38]
Reproductive system EC Upregulated — Normal endometrial tissues from 20 non-cancer patients versus tumor tissues from 68 EC patients [22]
CxCa Upregulated — Paracancerous tissues versus tumor tissues from 27 cxca patients [25]
Upregulated — Serum specimens from 24 women with localized disease versus serum specimens from 25 women with metastatic disease [24]
Upregulated HcerEpiC versus HeLa, CaSki, SiHa, and C33A Paracancerous tissues versus fresh cxca tissues from 70 cxca patients [23]
Upregulated — 50 FFPE normal cervical tissue samples versus 66 FFPE cxca tissue samples [5]
BrC Downregulated MCF-10A versus MDA-MB-231, MCF-7, MDA-MB-453, ZR-75, and T47-D Paracancerous tissues versus locally invasive breast tumors tissues from brc patients [27]
Upregulated — Paracancerous tissues versus tumor tissues from 40 brc patients; serum samples from 30 healthy people versus serum samples from 30 brc patients [26]
Motor system SaOS Downregulated hFOB1.19 versus MG-63, SAOS-2, HOS, and U2OS Paracancerous tissues versus tumor tissues from 38 saos patients [39]
COF Downregulated — Bone tissues from 10 healthy people versus bone tissues from 9 COF patients [3]
GBM, glioblastoma; LGG, brain lower grade glioma; NPC, nasopharyngeal carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; NSCLC, non-small-cell lung cancer; SCC, squamous cell carcinoma; TSCC, tongue squamous cell carcinoma; ECa, esophageal cancer; GC, gastric cancer; HCC, hepatocellular carcinoma; CRC, colorectal cancer; EC, endometrial carcinoma; CxCa, cervical cancer; BrC, breast cancer; SaOS, osteosarcoma; COF, cemento-ossifying fibroma.
WResearchers downloaded the TCGA (pan-cancer) dataset from the UCSC Xena database (https://xenabrowser.net  (accessed on 20 June 2022)). WeResearchers extracted miR-944 expression data (RPM) in 33 cancer samples and performed log2(RPM+1) transformation. WeResearchers excluded cancer types with <3 control samples and finally retrieved miR-944 expression data in 16 TCGA cancer types. WeResearchers calculated the quantile percentage of miR-944 expression among all non-zero-expressed miRNAs in each of these 16 cancer types. As shown in Figure 1A, miR-944 was highly expressed in nine tumors (0.75–1.0 quantile, Q4), while miR-944 was moderately expressed in other seven tumors (0.5–0.75 quantile, Q3).
Figure 1. Pan-cancer analysis of miR-944 based on TCGA database. (A) Histogram of median quantile expression of miR-944 in non-tumor and tumor groups in the TCGA database. The blue font indicates that miR-944 is significantly low expressed in this cancer type; the red font indicates that miR-944 is significantly highly expressed in this cancer type; (B) comparison of miR-944 expression levels between non-tumor and tumor groups in the TCGA database. *** means p < 0.0000625; ** means p < 0.000625; * means p < 0.003125; ns means no significant difference; (C) overview of SNVs of TP63; (D) mutation types in TP63 protein domains in various cancers; (E) differences in the expression level of miR-944 between the TP63 mutant group (Mut) and the wild group (WT). Ns means no significant difference. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; STAD, stomach adenocarcinoma; SKCM, skin cutaneous melanoma; TGCT, testicular germ cell tumor; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma.
WResearchers compared differences in miR-944 expression between non-tumor and tumor samples of 16 cancer types (unpaired Wilcoxon test, R version 4.1.3). As shown in  Table 2 and Figure 1B, Wresearchers found that miR-944 was significantly upregulated in five tumors (BLCA, HNSC, LUSC, THCA, and UCEC); significantly downregulated in two tumors (BRCA and PRAD) (Figure 1B). Notably, ourthe TCGA analysis demonstrated the association of miR-944 expression with cancer risk in bladder cancer, head and neck squamous cell carcinoma (HNSCC), thyroid cancer, and prostate cancer, which has not been reported yet.
Table 2.
 Comparison of miR-944 in TCGA dataset with existing data.
TCGA Cancers Sample Size (T/N) miR-944 Expression in TCGA miR-944 Expression in the Present Studies
BLCA
]
Q3, 0.5–0.75 quantile; Q4, 0.75–1.0 quantile; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; GBM, glioblastoma; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PRAD, prostate adenocarcinoma; STAD, stomach adenocarcinoma; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma.
WResearchers also calculated differences in the expression of miR-944 between patients of different genders or races based on the TCGA database. The results were shown in  Figure S1. There was no significant difference in the expression level of miR-944 between males and females in cancer. In BLCA and ESCA, the level of miR-944 in whites was significantly lower than that in other races.

4. Co-Expression of TP63 Transcripts and miR-944

miR-944 is located in the TP63. Previous studies have shown that ΔNp63, but not TAp63, can directly regulate the expression level of miR-944 by recruiting the transcription factor AP-2 [19]. The high correlation between the expression of TAp63 and miR-944 may be due to the common upstream regulators of TAp63 and ΔNp63, resulting in a significant positive correlation between TAp63 and ΔNp63. In order to explore the relationship between TP63 and miR-944, wresearchers obtained the expression data of miR-944, TAp63, and ΔNp63 in TCGA (pan-cancer) from the UCSC Xena database (https://xenabrowser.net (accessed on 20 June 2022)). Among 30 cancer types, wresearchers calculated pairwise correlations between miR-944, TP63, and ΔNp63 (Pearson’s correlation test). As shown in  Figure 2, miR-944 expression was significantly positively correlated with TAp63 and ΔNp63 in 15 and 16 cancers, respectively (p < 0.01 and r > 0.5). In ACC, CHOL, OV, PCPG, and READ, the expression level of miR-944 was not significantly correlated with TAp63 and ΔNp63 (p > 0.05 or r < 0.3). Among them, the number of ACC (n = 19) and CHOL (n = 20) samples is small, which may lead to the above insignificant correlation. In KIRC and KICH, the expression of miR-944 was not significantly correlated with ΔNp63 (p > 0.05 or r < 0.3) but had a positive correlation with TAp63 (p < 0.01 and r > 0.45), suggesting that there may be a different regulatory mechanism of miR-944 expression in KIRC and KICH.
Figure 2. The correlation of miR-944 with TP63 CNV, TAp63, and ΔNp63. The figure indicates the position of hsa-mir-944 in the TP63 gene and shows the correlation of miR-944 with TP63 CNV and the expression of TAp63 and ΔNp63. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; STAD, stomach adenocarcinoma; SKCM, skin cutaneous melanoma; TGCT, testicular germ cell tumor; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma.

References

  1. Ha, M.; Kim, V.N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 2014, 15, 509–524.
  2. Lee, H.Y.; Han, S.S.; Rhee, H.; Park, J.H.; Lee, J.S.; Oh, Y.M.; Choi, S.S.; Shin, S.H.; Kim, W.J. Differential expression of microRNAs and their target genes in non-small-cell lung cancer. Mol. Med. Rep. 2015, 11, 2034–2040.
  3. Pereira, T.; Brito, J.A.R.; Guimaraes, A.L.S.; Gomes, C.C.; de Lacerda, J.C.T.; de Castro, W.H.; Coimbra, R.S.; Diniz, M.G.; Gomez, R.S. MicroRNA profiling reveals dysregulated microRNAs and their target gene regulatory networks in cemento-ossifying fibroma. J. Oral Pathol. Med. 2018, 47, 78–85.
  4. Zou, Y.; Zhong, C.; Hu, Z.; Duan, S. MiR-873-5p: A Potential Molecular Marker for Cancer Diagnosis and Prognosis. Front. Oncol. 2021, 11, 743701.
  5. Park, S.; Kim, J.; Eom, K.; Oh, S.; Kim, S.; Kim, G.; Ahn, S.; Park, K.H.; Chung, D.; Lee, H. microRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer. BMC Cancer 2019, 19, 419.
  6. Zhong, C.; Xie, Z.; Zeng, L.H.; Yuan, C.; Duan, S. MIR4435-2HG Is a Potential Pan-Cancer Biomarker for Diagnosis and Prognosis. Front. Immunol. 2022, 13, 855078.
  7. Liu, R.; Zhou, M.; Zhang, P.; Zhao, Y.; Zhang, Y. Cell proliferation and invasion is promoted by circSERPINA3 in nasopharyngeal carcinoma by regulating miR-944/MDM2 axis. J. Cancer 2020, 11, 3910–3918.
  8. Tang, J.; Gao, W.; Liu, G.; Sheng, W.; Zhou, J.; Dong, Q.; Dong, M. miR-944 Suppresses EGF-Induced EMT in Colorectal Cancer Cells by Directly Targeting GATA6. Oncol. Targets Ther. 2021, 14, 2311–2325.
  9. Wen, L.; Li, Y.; Jiang, Z.; Zhang, Y.; Yang, B.; Han, F. miR-944 inhibits cell migration and invasion by targeting MACC1 in colorectal cancer. Oncol. Rep. 2017, 37, 3415–3422.
  10. Lv, W.; Tan, Y.; Xiong, M.; Zhao, C.; Wang, Y.; Wu, M.; Wu, Y.; Zhang, Q. Analysis and validation of m6A regulatory network: A novel circBACH2/has-miR-944/HNRNPC axis in breast cancer progression. J. Transl. Med. 2021, 19, 527.
  11. Zhang, L.; Wu, Y.; Hou, C.; Li, F. Circ_0072088 knockdown contributes to cisplatin sensitivity and inhibits tumor progression by miR-944/LASP1 axis in non-small cell lung cancer. J. Gene Med. 2022, 24, e3414.
  12. Chen, X.; Guo, Z.; Fan, S.; Sun, L.; Li, H.; Zhou, J.; Li, Y. Integrating microRNA and mRNA expression in rapamycin-treated T-cell acute lymphoblastic leukemia. Pathol. Res. Pract. 2019, 215, 152494.
  13. Xi, L.; Liu, Q.; Zhang, W.; Luo, L.; Song, J.; Liu, R.; Wei, S.; Wang, Y. Circular RNA circCSPP1 knockdown attenuates doxorubicin resistance and suppresses tumor progression of colorectal cancer via miR-944/FZD7 axis. Cancer Cell Int. 2021, 21, 153.
  14. Long, X.; Zheng, M.; Yang, Y.; Chen, Y.; Zhang, X.; Zhang, H. circ_ZFR Is Linked to Paclitaxel Resistance in Cervical Cancer via miR-944 Sponging and IL-10 Upregulation. Anal. Cell Pathol. 2022, 2022, 4807287.
  15. Zhu, H.; Lu, Q.; Lu, Q.; Shen, X.; Yu, L. Matrine Regulates Proliferation, Apoptosis, Cell Cycle, Migration, and Invasion of Non-Small Cell Lung Cancer Cells Through the circFUT8/miR-944/YES1 Axis. Cancer Manag. Res. 2021, 13, 3429–3442.
  16. Lin, B.Z.; Wan, S.Y.; Lin, M.Y.; Chang, C.H.; Chen, T.W.; Yang, M.H.; Lee, Y.J. Involvement of Differentially Expressed microRNAs in the PEGylated Liposome Encapsulated (188)Rhenium-Mediated Suppression of Orthotopic Hypopharyngeal Tumor. Molecules 2020, 25, 3609.
  17. Kim, K.H.; Cho, E.G.; Yu, S.J.; Kang, H.; Kim, Y.J.; Kim, S.H.; Lee, T.R. DeltaNp63 intronic miR-944 is implicated in the DeltaNp63-mediated induction of epidermal differentiation. Nucleic Acids Res. 2015, 43, 7462–7479.
  18. Prieto-Garcia, C.; Hartmann, O.; Reissland, M.; Braun, F.; Fischer, T.; Walz, S.; Schulein-Volk, C.; Eilers, U.; Ade, C.P.; Calzado, M.A.; et al. Maintaining protein stability of Np63 via USP28 is required by squamous cancer cells. EMBO Mol. Med. 2020, 12, e11101.
  19. Kim, J.; Park, S.; Chang, Y.; Park, K.H.; Lee, H. Synergetic Effects of Intronic Mature miR-944 and DeltaNp63 Isoforms on Tumorigenesis in a Cervical Cancer Cell Line. Int. J. Mol. Sci. 2020, 21, 5612.
  20. Warnecke-Eberz, U.; Chon, S.H.; Holscher, A.H.; Drebber, U.; Bollschweiler, E. Exosomal onco-miRs from serum of patients with adenocarcinoma of the esophagus: Comparison of miRNA profiles of exosomes and matching tumor. Tumour Biol. 2015, 36, 4643–4653.
  21. Ma, J.; Mannoor, K.; Gao, L.; Tan, A.; Guarnera, M.A.; Zhan, M.; Shetty, A.; Stass, S.A.; Xing, L.; Jiang, F. Characterization of microRNA transcriptome in lung cancer by next-generation deep sequencing. Mol. Oncol. 2014, 8, 1208–1219.
  22. He, Z.; Xu, H.; Meng, Y.; Kuang, Y. miR-944 acts as a prognostic marker and promotes the tumor progression in endometrial cancer. Biomed. Pharmacother. 2017, 88, 902–910.
  23. Chen, Y.; Gu, Y.; Gu, Y.; Wu, J. Long Noncoding RNA LINC00899/miR-944/ESR1 Axis Regulates Cervical Cancer Cell Proliferation, Migration, and Invasion. J. Interferon Cytokine Res. 2021, 41, 220–233.
  24. Palatnik, A.; Ye, S.; Kendziorski, C.; Iden, M.; Zigman, J.S.; Hessner, M.J.; Rader, J.S. Identification of a serum-induced transcriptional signature associated with metastatic cervical cancer. PLoS ONE 2017, 12, e0181242.
  25. Xie, H.; Lee, L.; Scicluna, P.; Kavak, E.; Larsson, C.; Sandberg, R.; Lui, W.O. Novel functions and targets of miR-944 in human cervical cancer cells. Int. J. Cancer 2015, 136, E230–E241.
  26. He, H.; Tian, W.; Chen, H.; Jiang, K. MiR-944 functions as a novel oncogene and regulates the chemoresistance in breast cancer. Tumour Biol. 2016, 37, 1599–1607.
  27. Flores-Perez, A.; Marchat, L.A.; Rodriguez-Cuevas, S.; Bautista, V.P.; Fuentes-Mera, L.; Romero-Zamora, D.; Maciel-Dominguez, A.; de la Cruz, O.H.; Fonseca-Sanchez, M.; Ruiz-Garcia, E.; et al. Suppression of cell migration is promoted by miR-944 through targeting of SIAH1 and PTP4A1 in breast cancer cells. BMC Cancer 2016, 16, 379.
  28. Jiang, J.; Lu, J.; Wang, X.; Sun, B.; Liu, X.; Ding, Y.; Gao, G. Glioma stem cell-derived exosomal miR-944 reduces glioma growth and angiogenesis by inhibiting AKT/ERK signaling. Aging 2021, 13, 19243–19259.
  29. Ji, J.; Peng, Y.; Niu, T.; Lin, Y.; Lin, Y.; Li, X.; Wu, X.; Huang, Z.; Zhong, L.; Zhang, S. miR-944 inhibits cell migration and invasion by targeting MACC1 in nasopharyngeal carcinoma. Int. J. Clin. Exp. Pathol. 2018, 11, 1167–1174.
  30. An, J.C.; Shi, H.B.; Hao, W.B.; Zhu, K.; Ma, B. miR-944 inhibits lung adenocarcinoma tumorigenesis by targeting STAT1 interaction. Oncol. Lett. 2019, 17, 3790–3798.
  31. Lv, J.; Li, Q.; Ma, R.; Wang, Z.; Yu, Y.; Liu, H.; Miao, Y.; Jiang, S. Long Noncoding RNA FGD5-AS1 Knockdown Decrease Viability, Migration, and Invasion of Non-Small Cell Lung Cancer (NSCLC) Cells by Regulating the MicroRNA-944/MACC1 Axis. Technol. Cancer Res. Treat. 2021, 20, 1533033821990090.
  32. Geng, H.; Li, S.; Xu, M. Long Noncoding RNA SNHG6 Functions as an Oncogene in Non-Small Cell Lung Cancer via Modulating ETS1 Signaling. Oncol. Targets Ther. 2020, 13, 921–930.
  33. Lin, C.; Zou, Y.; Li, R.; Liu, D. Long noncoding RNA PRNCR1 exerts oncogenic effects in tongue squamous cell carcinoma in vitro and in vivo by sponging microRNA944 and thereby increasing HOXB5 expression. Int. J. Mol. Med. 2020, 46, 119–130.
  34. Ma, S.; Gu, X.; Shen, L.; Chen, Y.; Qian, C.; Shen, X.; Ju, S. CircHAS2 promotes the proliferation, migration, and invasion of gastric cancer cells by regulating PPM1E mediated by hsa-miR-944. Cell Death Dis. 2021, 12, 863.
  35. Pan, T.; Chen, W.; Yuan, X.; Shen, J.; Qin, C.; Wang, L. miR-944 inhibits metastasis of gastric cancer by preventing the epithelial-mesenchymal transition via MACC1/Met/AKT signaling. FEBS Open Bio 2017, 7, 905–914.
  36. Zheng, H.; Zou, A.E.; Saad, M.A.; Wang, X.Q.; Kwok, J.G.; Korrapati, A.; Li, P.; Kisseleva, T.; Wang-Rodriguez, J.; Ongkeko, W.M. Alcohol-dysregulated microRNAs in hepatitis B virus-related hepatocellular carcinoma. PLoS ONE 2017, 12, e0178547.
  37. Kim, Y.J.; Lee, J.H.; Jin, S.; Kim, J.H.; Kim, S.H. Primate-specific miR-944 activates p53-dependent tumor suppression in human colorectal cancers. Cancer Lett. 2019, 440–441, 168–179.
  38. Tang, J.T.; Zhao, J.; Sheng, W.; Zhou, J.P.; Dong, Q.; Dong, M. Ectopic expression of miR-944 impairs colorectal cancer cell proliferation and invasion by targeting GATA binding protein 6. J. Cell Mol. Med. 2019, 23, 3483–3494.
  39. Yan, T.; Zhu, S.; Zhang, J.; Lu, G.; Lv, C.; Wei, Y.; Luo, M. MicroRNA944 targets vascular endothelial growth factor to inhibit cell proliferation and invasion in osteosarcoma. Mol. Med. Rep. 2018, 18, 5221–5228.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback